PacBio Grants Equity Incentive Award to New Employee
PacBio (NASDAQ: PACB) announced the granting of stock options and restricted stock units (RSUs) totaling 150,000 shares to a newly hired employee under the 2020 Inducement Equity Incentive Plan, effective February 22, 2022. The options have an exercise price of $10.32 per share, matching the closing stock price on the effective date. The vesting schedule includes a one-year cliff and monthly vesting thereafter for the options, while the RSUs will vest annually over four years.
- Granting of 100,000 stock options and 50,000 RSUs may enhance employee retention and motivation.
- The exercise price of options reflects the current market value, indicating alignment with shareholder interests.
- None.
MENLO PARK, Calif., Feb. 25, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of PacBio common stock, and restricted stock units (“RSUs”) covering 50,000 shares of PacBio common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”) effective on February 22, 2022.
The 2020 Inducement Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of PacBio as an inducement material to such individual’s entering into employment with PacBio in accordance with Nasdaq Marketplace Rule 5635(c)(4).
The options have an exercise price of
About PacBio
Pacific Biosciences of California, Inc. is empowering life scientists with highly accurate sequencing platforms. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Contacts
Investors:
Todd Friedman
650.521.8450
ir@pacificbiosciences.com
Media:
Lizelda Lopez
pr@pacificbiosciences.com
FAQ
What did PacBio announce on February 25, 2022?
What is the exercise price of the stock options granted by PacBio?
How is the vesting schedule structured for the stock options at PacBio?